ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
26.44
0.43
(1.65%)
Closed January 24 4:00PM
26.46
0.02
(0.08%)
After Hours: 6:17PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
26.46
Bid
-
Ask
-
Volume
40,948,835
25.85 Day's Range 26.4782
24.48 52 Week Range 31.54
Market Cap
Previous Close
26.01
Open
26.01
Last Trade
5
@
26.44
Last Trade Time
Financial Volume
$ 1,075,201,464
VWAP
26.2572
Average Volume (3m)
42,973,459
Shares Outstanding
5,666,990,035
Dividend Yield
6.50%
PE Ratio
70.71
Earnings Per Share (EPS)
0.37
Revenue
58.5B
Net Profit
2.12B

About Pfizer Inc

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers includ... Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
New York, New York, USA
Founded
-
Pfizer Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker PFE. The last closing price for Pfizer was $26.01. Over the last year, Pfizer shares have traded in a share price range of $ 24.48 to $ 31.54.

Pfizer currently has 5,666,990,035 shares outstanding. The market capitalization of Pfizer is $147.40 billion. Pfizer has a price to earnings ratio (PE ratio) of 70.71.

Pfizer (PFE) Options Flow Summary

Overall Flow

Bullish

Net Premium

83M

Calls / Puts

1,410.34%

Buys / Sells

91.01%

OTM / ITM

14.66%

Sweeps Ratio

2.51%

PFE Latest News

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would be the...

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.361.3793103448326.126.6425.963597213626.35120611CS
4-0.16-0.60105184072126.6227.5725.963353393926.57521236CS
12-1.99-6.9947275922728.4528.6424.484297345926.1915646CS
26-3.17-10.698616267329.6331.5424.483642781727.69283644CS
52-1.94-6.8309859154928.431.5424.483796746027.6253243CS
156-25.26-48.839907192651.7256.3224.483018349435.58534477CS
260-13.77-34.228187919540.2361.7124.483140380837.66579461CS

PFE - Frequently Asked Questions (FAQ)

What is the current Pfizer share price?
The current share price of Pfizer is $ 26.46
How many Pfizer shares are in issue?
Pfizer has 5,666,990,035 shares in issue
What is the market cap of Pfizer?
The market capitalisation of Pfizer is USD 147.4B
What is the 1 year trading range for Pfizer share price?
Pfizer has traded in the range of $ 24.48 to $ 31.54 during the past year
What is the PE ratio of Pfizer?
The price to earnings ratio of Pfizer is 70.71
What is the cash to sales ratio of Pfizer?
The cash to sales ratio of Pfizer is 2.56
What is the reporting currency for Pfizer?
Pfizer reports financial results in USD
What is the latest annual turnover for Pfizer?
The latest annual turnover of Pfizer is USD 58.5B
What is the latest annual profit for Pfizer?
The latest annual profit of Pfizer is USD 2.12B
What is the registered address of Pfizer?
The registered address for Pfizer is 235 EAST 42ND STREET, NEW YORK, NEW YORK, 10017
What is the Pfizer website address?
The website address for Pfizer is www.pfizer.com
Which industry sector does Pfizer operate in?
Pfizer operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VNCEVince Holding Corp
$ 3.90
(65.96%)
134.88M
SESSES AI Corporation
$ 1.11
(33.51%)
227.67M
ENFYEnlightify Inc
$ 1.26
(32.63%)
162.23k
WNSWNS Holdings Limited
$ 60.71
(22.65%)
1.5M
TALTal Education Group
$ 11.075
(21.30%)
28.59M
EVTLVertical Aerospace Ltd
$ 5.35
(-42.35%)
4.89M
LOBLive Oak Bancshares Inc
$ 35.08
(-13.94%)
427.95k
PERFPerfect Corp
$ 2.445
(-12.99%)
431.72k
LITBLightInTheBox Holding Co Ltd
$ 1.11
(-11.90%)
15.38k
PSNParsons Corporation
$ 85.34
(-10.04%)
5.65M
SESSES AI Corporation
$ 1.11
(33.51%)
227.63M
VNCEVince Holding Corp
$ 3.90
(65.96%)
134.87M
QBTSD Wave Quantum Inc
$ 6.035
(-3.44%)
86.95M
FFord Motor Company
$ 10.1601
(1.30%)
56.19M
CHPTChargePoint Holdings Inc
$ 0.9423
(-4.49%)
52.74M

PFE Discussion

View Posts
Monroe1 Monroe1 5 hours ago
So why would they ever want to hide this info? Well, if the published it like they are supposed to, and follow their guidelines then no one would be upset and they would just say NO!! I am not taking that shit no way Jose.
https://icandecide.org/press-release/breaking-ican-acquires-critical-fda-safety-reports-concerning-covid-19-vaccines-after-years-of-litigation/
👍️0
Vexari Vexari 1 day ago
Time will tell
So I ask you. Would you be curious to know .....
A whole lot of so called professionals need to go to jail... or worse.
https://kirschsubstack.com/p/breaking-ican-acquires-critical-fda?publication_id=548354&post_id=155479991&isFreemail=true&r=x7hm&triedRedirect=true Certain protective laws

Were reversed

Immunity

Being one

Accountably

Coming to a theater

Near you
🎃 1 👎️ 1 💊 1 🗑️ 1 🤪 1
Monroe1 Monroe1 1 day ago
So I ask you. Would you be curious to know .....
A whole lot of so called professionals need to go to jail... or worse.
https://kirschsubstack.com/p/breaking-ican-acquires-critical-fda?publication_id=548354&post_id=155479991&isFreemail=true&r=x7hm&triedRedirect=true
👍️0
Monroe1 Monroe1 1 day ago
https://rumble.com/v6b2g9m-rumble-scott-gottleib-rfk-hallow.html
👍️0
Monroe1 Monroe1 3 days ago
Last minute gift from the government of losers rewarding their participation in the killing scam. Hopefully, the new head of Health and Human Services can eliminate the pay off. https://www.biospace.com/business/moderna-nabs-another-590m-from-hhs-for-mrna-based-bird-flu-vaccines?_hsenc=p2ANqtz--ERBJZ-k40VmndW8EdkujcqIVdSgLdPDOhmURPkjH71KHi0_-AVdlXL3JLEizk881LrP7CahljNSikSLxKpKJP9k-Fqw&_hsmi=343444816
👍️0
Monroe1 Monroe1 3 days ago
they need to do something good to turn the ship around. the company can certainly look forward to more scrutiny now that there is a new sheriff in town.
👍️0
DewDiligence DewDiligence 1 week ago
PFE raises $3.1B cash by paring HLN stake (as reported yesterday by Bloomberg). After the sale PFE’s HLN stake is reduced from 15% to 7.3%, which means that PFE has another (roughly) $3B source of capital whenever it wants.
👆️ 1 👍 1 💯 1
Monroe1 Monroe1 1 week ago
This is a long way from where it once was. Yet the company is hemorrhaging. Still they up the dividend to slow the bleeding.
This is a long way from over. The biggest scam in world history just won't go away.
https://givemefive.news/dod-ignored-herd-immunity-data-before-vaccine-mandate/
👍️0
axelvento axelvento 2 weeks ago
has announced that it will be paying its dividend of $0.43 on the 7th of March, an increased payment from last year's comparable dividend. This makes the dividend yield 6.5%, which is above the industry average

$PFE
👆️ 1 👍 1 😀 1
axelvento axelvento 2 weeks ago
so it seems
👍️0
Monroe1 Monroe1 2 weeks ago
is that in competition with Keytruda?
👍️0
Vexari Vexari 2 weeks ago
FDA Mandates Nerve Damage Warnings for 2 RSV Vaccines

Respiratory syncytial virus (RSV) activity is currently deemed to be ‘very high’ in many parts of the United States, according to CDC.

By Naveen Athrappully
1/9/2025 Updated: 1/10/2025

The U.S. Food and Drug Administration (FDA) ordered two respiratory syncytial virus (RSV) vaccine manufacturers to include a potentially paralytic side effect warning related to nerve damage on product labels.

The manufacturers, GSK and Pfizer, manufacturing Arexvy and Abrysvo vaccines respectively, must now include a warning stating a risk of Guillain-Barre syndrome (GBS) following vaccination, according to a Jan. 7 statement from the agency.

GBS is a rare disorder in which the immune system ends up damaging nerve cells, which leads to weakness in the muscles and potential near-total paralysis, depending on severity.

RSV is a common respiratory virus that infects the throat, nose, and lungs, and typically spreads during fall and winter seasons. Infected people can experience symptoms similar to that of a common cold such as a runny nose, congestion, sneezing, and coughing.

The FDA said the following statement is to be included in the Warnings and Precautions section of the two vaccines: “The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with Abrysvo” or with “Arexvy” for that vaccine.

Arexvy is used by people aged 50 and older to deal with lower respiratory tract disease caused by RSV, while Abrysvo has been approved for use in adults aged 18 and above.

The labeling requirement follows an observational study conducted by the FDA.

In the study, the agency found there was an “increased risk of GBS during the 42 days following vaccination, with an estimated 9 excess cases of GBS per million doses of Abrysvo, and an estimated 7 excess cases of GBS per million doses of Arexvy administered to individuals 65 years of age and older.”

However, despite these results, the FDA determined that “the benefits of vaccination with Abrysvo and Arexvy continue to outweigh their risks.”

According to the U.S. Centers for Disease Control and Prevention (CDC), early symptoms of GBS can include feelings of weakness and tingling.

“People with GBS usually first feel these symptoms in both legs. Then, they might feel these symptoms in their arms and upper body,” it said. “Symptoms can progress over hours, days, or weeks.” The weakness keeps increasing until people are unable to use certain muscles.

“People with GBS need to be hospitalized,” the agency said. “Most people start to recover 2–3 weeks after symptoms start. Recovery may take as little as a few weeks or as long as a few years. Most people recover fully, but some have permanent nerve damage. Some people have died from GBS.”

The Epoch Times reached out to GSK and Pfizer for comment.


RSV Vaccine Usage and Risks

The RSV vaccine label update comes as the overall respiratory illness activity in the United States is deemed to be at a “high” level, with RSV activity being “very high in many areas of the country, particularly in young children,” according to the CDC.

“Emergency department visits and hospitalizations are highest in children and hospitalizations are elevated among older adults in some areas.”

The agency recommends all babies be protected from RSV by either vaccinating mothers or by giving an antibody to the infant.

Even if the mother is not at high risk for severe RSV, the vaccination is important since the pregnant woman will “pass the protection” to her baby, the CDC said. “It takes two weeks to develop protection (antibodies) and for protection to pass on to your baby.”

This protection lasts for the first six months of the infant’s life “while they are at highest risk of severe RSV.”

Pregnant women who have already taken an RSV vaccine during a previous pregnancy are not recommended to take it again. Instead, the baby should get nirsevimab, an antibody.

CDC recommends antibodies to “all babies younger than eight months of age born to mothers who did not receive a maternal RSV vaccine (Pfizer’s Abrysvo) during pregnancy.”

For older adults, the CDC advises vaccination for 60 to 74-year-olds who are at increased risk of severe RSV and for all individuals aged 75 and above.

However, the agency warns that vaccination could result in certain adverse events. “Side effects such as pain, redness, and swelling where the shot is given, fatigue, fever, headache, nausea, diarrhea, and muscle or joint pain may occur after you get an RSV vaccine.”

“These side effects are usually mild. Patients who have experienced these symptoms when getting other vaccines might be more likely to experience them after getting an RSV vaccine,” it said.

Epoch Times
Subscription necessary to read on site
🎃 1 💊 1 🗑️ 1 🤪 1
axelvento axelvento 2 weeks ago
if approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
👆️ 1 👍️ 1
Monroe1 Monroe1 2 weeks ago
More phuzzy phyzer prhoblems https://www.theepochtimes.com/health/fda-mandates-nerve-damage-warnings-for-2-rsv-vaccines-5789027?src_src=healthnoe&src_cmp=health-2025-01-10&est=AAAAAAAAAAAAAAAAdbAmeh0exsTo9bIGsWoXCLt3DMv%2BeZd%2FEugtIdyHPONOLA%3D%3D
👍️ 1
Vexari Vexari 2 weeks ago
Create a problem

Time reaction

Solve problem

Media controls

The agenda

Who controls

The media

Getting

Close
💊 1 🗑️ 1 🚽 1 🤪 1
axelvento axelvento 2 weeks ago
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda

https://www.biospace.com/drug-development/pfizers-subcutaneous-pd-1-blocker-aces-phase-iii-in-bladder-cancer-carves-niche-versus-keytruda
👍 1 💪 2 💯 2
biotech_researcher biotech_researcher 2 weeks ago
$PFE One good bullish news. 

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer.

In terms of bladder cancer, market size is almost 4b in 2023. This is growing and expected to be  5.5b.

At least few dollar worth asset for the stock. 
Thank you very much for the hard work PFE.
👆️ 1 👍️ 1 💪 1
Vexari Vexari 2 weeks ago
Why did Pfizer stop testing on animals

What about human testing
🕳️ 1 🗑️ 1 🫵 1
Vexari Vexari 2 weeks ago
What are the ingredients?

In the next round

Of vaccines
👎️ 1 💊 1 🕳️ 1 🗑️ 1 🤪 1
biotech_researcher biotech_researcher 2 weeks ago
Vexari, any questions???
👍️0
biotech_researcher biotech_researcher 3 weeks ago
PFE on fire! Market sees right through the nonsense...  ST target: $30
👍️ 2 💯 1
Monroe1 Monroe1 3 weeks ago
keep digging mister propaganda: https://petermcculloughmd.substack.com/p/new-study-covid-19-mrna-injections?publication_id=1119676&post_id=154280211&isFreemail=true&r=x7hm&triedRedirect=true

Cleveland Clinic
👍️0
biotech_researcher biotech_researcher 3 weeks ago
Nope...
👍️0
biotech_researcher biotech_researcher 3 weeks ago
Nope....
👍️0
Vexari Vexari 3 weeks ago
Interesting

To say the least

Dive bomber

In and out
🎃 1 👎️ 1 💊 1 🗑️ 1 🤪 1
Monroe1 Monroe1 3 weeks ago
https://www.statista.com/statistics/1318652/covid-vaccine-lawsuits-industry/
👍️0
Monroe1 Monroe1 3 weeks ago
yes, it will get better after bankruptcy. I plan on buying in at that time or instruct my grand kids to do so.
👍️0
Monroe1 Monroe1 3 weeks ago
why no answer? perhaps mr. biotick works for pfizzer.
👍️0
Monroe1 Monroe1 3 weeks ago
How many people get it? The spike protein stays in the body and continues to do damage as you age.
Do investors think this is going away any time soon especially now that some real honest folks are about
to run the show? Tik Tok
https://petermcculloughmd.substack.com/p/catastrophic-neurological-and-psychiatric?publication_id=1119676&post_id=154201714&isFreemail=true&r=x7hm&triedRedirect=true
👍️0
Vexari Vexari 3 weeks ago
Why would that be?
Complete horse hockey..
👍️ 1 💨 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
biotech_researcher biotech_researcher 3 weeks ago
Complete horse hockey..
👍️ 1 💥 1 💯 1
Vexari Vexari 3 weeks ago
The bird

Is a metamorphical germ

Eating

Dead cell debris
👎️ 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
Vexari Vexari 3 weeks ago
Can not catch something that doesn't exist

Facts don't lie

Open to board discussion
👎️ 1 🗑️ 1 🤥 1 🤪 1 🫵 1
Monroe1 Monroe1 3 weeks ago
Yep, otherwise they would not be cutting out even some of the most promising collaborations. They are going to have scrap others too in order to stave off bankruptcy possibility in the near future with the pending and growing lawsuits. Other surprises may be waiting too in the form of new and real scrutiny by RFKjr
and the new FDA commissioner. Things are looking ugly and Pfizer is going to pay the consequences for cheating the system, withholding data, and corrupt political collaborations. Not good Pfizer. Looking for investor lawsuits to gain strength.
https://www.businesswire.com/news/home/20241230895593/en/Sangamo-Therapeutics-to-Regain-Full-Rights-to-Hemophilia-A-Gene-Therapy-Program-Following-Pfizer%E2%80%99s-Decision-to-Cease-Development-of-Giroctocogene-Fitelparvovec
👍️0
IHuser IHuser 3 weeks ago
imo...

Wikipedia • Coronavirus disease 2019 is a contagious disease caused by the coronavirus SARS-CoV-2. The disease spread worldwide, resulting in the COVID-19 pandemic.
The symptoms of COVID-19 can vary but often include fever, fatigue, cough, breathing difficulties, loss of smell, and loss of taste.

Like a snake bit me...... PFE



PFE


(shivering)


IHuser
👍️0
Saving Grace Saving Grace 4 weeks ago
Yup, this horseshit is being pumped by Wall Street crooks, cooking the books. It's over for big pharma.

Eli Lilly and Company & Pfizer Inc. are a disaster in the making.

👍️0
Vexari Vexari 4 weeks ago
When financial guidance

Is based on a lie

Where does one go

From there
👎️ 1 🕳️ 1 🗑️ 1 🚽 2 🤪 1
Vexari Vexari 4 weeks ago
They knew what they were doing

Nothing can stop

What is coming
🎃 1 👎️ 2 💊 1 🗑️ 1 🧻 1
IHuser IHuser 4 weeks ago
imo...you are postulating and swaying perception without addressing the science or patents for insured improved health... yea that's because.. I have the market on my side....especially the women now.....and this pos is a done issue stick a fork in it and go play in traffic.....-look at the share price now blue boy ~


PFE





IHuse4
👍️0
IHuser IHuser 4 weeks ago
imo...you are very provacative and could wind up bankrupting this entire scam...and should be mindful of the implications...PFE


OK~ go fuck off




PFE



IHuser
👍️0
IHuser IHuser 4 weeks ago
imo...Pfizer sponsoring New Years Cornhole tournament in the Hamptons..... get signed up for Viagra CORN Holing into the new year with your billionaire pals.... ...don't say we didn't tell you about a good time and bid flu shots and Polio supplements are door prizes!! , Yaaaaaaay


PFE




IHuser
👍️0
Vexari Vexari 4 weeks ago
Gaining strength

Against the cartels grip

Tide is turning

Retribution

Is near
🎃 1 👍️ 1 👎️ 1 🕳️ 1 🗑️ 1 🚽 1
Monroe1 Monroe1 4 weeks ago
It's all about right and wrong. It is coming down to that. PFE will pay the piper.
👍️0
Vexari Vexari 4 weeks ago
The fall of the vaccine agenda

Is the fall of big pharma

The soul of humanity

Is being fought

In health care

Expanding awareness

Is key
👍️ 3 💊 2 🕳️ 1 🗑️ 1 🤪 2 ⤵️ 2
Saving Grace Saving Grace 4 weeks ago
Yes, It's over for big Pharma!

👍️ 1
Saving Grace Saving Grace 4 weeks ago
The gloves come off with Big Pharma 2025
👍️ 1
IHuser IHuser 4 weeks ago
imo...yes I am here to pump Pfizer biofunctionality in public restrooms....when my Peter pees and the bunghole is opened we are all about Pfizer watching what's going
On what's why I'm bullish

PFE



IHuser
👍️0
Vexari Vexari 4 weeks ago
Genocide must be gentle

So as not to alarm

Those chosen
🎃 1 👍️ 1 💊 1 🕳️ 1 🗑️ 1 🤪 1
MomsSpaghetti MomsSpaghetti 4 weeks ago
Pfizer has been exploring new treatments for mood disorders and has a longstanding interest in neurology. It has been over 12 years since their addition of Lyrica for GAD. Their acquisition of MindMed would complement their existing CNS pipeline, particularly for disorders such as anxiety.

Wonder if they would take on that small biotech. Anyone have thoughts?
👍️0
Monroe1 Monroe1 4 weeks ago
https://m3.gab.com/media_attachments/59/1a/1f/591a1f4955dfe351d818c6853909918b.webp?width=568
👍️ 2 👎️ 1 🤪 1

Your Recent History

Delayed Upgrade Clock